Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2021 Sustainability Report. The report highlights the...
MedTech stocks are trading sharply higher on Tuesday after the industry bellwether Johnson & Johnson (JNJ) reported better than expected 1Q 2022 sales for its MedTech segment. The iShares U.S. Medical Devices ETF (NYSEARCA:IHI) has recorded the best intraday gain since June 2020, dri...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quart...
Medical devices, healthcare equipment and healthcare supplies grew during the pandemic and the sector is expected to grow further. Equally distributed over 86 stocks, XHE is protected from market volatility risk. Higher price multiples provide an indication of investor confidence....
Glaukos (NYSE:GKOS) said it began a phase 2 program for its third generation iLink therapy to treat keratoconus, a type of eye disorder. Keratoconus occurs when the cornea thins and gradually bulges outward into a cone shape, causing blurred vision. The company's iLink platform cons...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generation iLi...
Glaukos Corporation (GKOS) Q4 2021 Earnings Conference Call February 22, 2022 16:30 ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - President & Chief Executive Officer Joe Gilliam - Chief Financial Officer Alex Thurman - Vice ...
Glaukos press release (NYSE:GKOS): Q4 Non-GAAP EPS of -$0.31 beats by $0.06. Revenue of $73.2M (flat Y/Y) beats by $5.93M. For further details see: Glaukos Non-GAAP EPS of -$0.31 beats by $0.06, revenue of $73.2M beats by $5.93M
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021....
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...